비교리스트

 카트 문의
시장보고서
상품코드
1370911

크립토콕쿠스증 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년) - 치료별, 유통 채널별, 지역별, 경쟁별 부문

Cryptococcosis Therapeutics Market, - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment, By Distribution Channel, By Region, By Competition.
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 190 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 크립토콕쿠스증 치료제 시장은 2022년에 46억 7,000만 달러로 평가되며, 2028년까지의 CAGR은 4.34%로 꾸준한 성장을 보이며, 2028년에는 60억 4,000만 달러에 달할 것으로 예측되고 있습니다.

크립토콕쿠스증은 주로 폐와 중추신경계 감염으로 나타나며, 경미한 호흡기 질환부터 심각한 신경학적 합병증까지 다양한 증상을 보입니다. 원인균은 환경, 특히 새의 배설물로 오염된 토양에 많이 존재합니다. 곰팡이 포자를 흡입하면 특히 감염되기 쉬운 사람에게 감염을 일으킬 수 있으며, HIV/AIDS의 유행, 장기 이식 및 기타 면역 억제 상태와 같은 요인으로 인해 면역 결핍 환자가 증가함에 따라 크립토코커스 증의 부담 증가에 크게 기여하고 있습니다. 연구 노력의 결과로 치료 옵션이 지속적으로 개선되면서 크립토콕쿠스증 치료제 시장은 성장할 수 있는 여건을 갖추고 있습니다. 제약사, 학계, 공공 의료기관의 협력은 이러한 혁신에 있으며, 매우 중요한 역할을 하고 있습니다. 새로운 항진균제, 병용요법 및 제제의 출현으로 크립토콕쿠스증 환자의 삶의 질과 생존율이 향상될 것으로 예상됩니다.

주요 시장 성장 촉진요인

면역결핍증 유병률 증가로 크립토콕쿠스증 치료제 시장 견인:최근 수년간 면역결핍증 환자 수가 눈에 띄게 급증하고 있습니다. 세계 HIV/AIDS의 유행은 여전히 크립토콕쿠스증 유병률에 큰 영향을 미치고 있으며, HIV 치료와 예방의 비약적인 발전에도 불구하고 여전히 많은 환자들이 적절한 치료를 받지 못해 크립토콕쿠스증과 같은 기회감염에 취약한 상황입니다. 장기 이식이나 암 치료의 보급은 환자들에게 새로운 희망을 주는 동시에 면역 체계를 약화시키고 있습니다. 의학의 발전으로 장기이식 환자나 암을 극복한 환자들의 수명이 길어지면서 면역력이 저하된 상태로 생활하는 인구가 증가하고 있습니다. 이러한 면역 결핍 환자의 크립토콕쿠스증 유병률 증가 추세는 크립토콕쿠스증 치료제 개발에 박차를 가하고 있습니다. 그 결과 이 시장에서는 연구개발이 급증하고 있습니다. 제약사들은 더 효과적이고 독성이 낮으며 더 많은 환자군이 사용할 수 있는 약물을 개발하기 위해 노력하고 있습니다. 크립토콕쿠스증 치료제로는 암포테리신 B, 플루코나졸, 플루시토신과 같은 항진균제가 있습니다. 그러나 이러한 약제들은 효과와 잠재적 부작용 측면에서 한계가 있으며, 혁신적인 치료법의 필요성이 대두되고 있습니다. 연구자들은 치료 결과를 개선하고 면역 결핍 환자의 크립토콕쿠스증 부담을 줄이기 위해 새로운 항진균 화합물, 병용요법, 면역조절제를 적극적으로 탐색하고 있습니다.

시장 개요
예측 기간 2024-2028
시장 규모 2022년 46억 7,000만 달러
2028년 시장 규모 60억 4,000만 달러
CAGR 2023-2028 4.34%
급성장 부문 풀 시토신
최대 시장 북미

공중보건 인식 증가로 크립토콕쿠스증 치료제 시장 성장 촉진공중보건 인식 증가로 인해 효과적인 크립토콕쿠스증 치료제에 대한 수요가 증가하고 있습니다. 이러한 수요는 크립토콕쿠스증 치료제 시장의 성장을 가속하고 있습니다. 제약회사와 연구자들은 이 진균 감염증과 싸우고 환자의 삶의 질을 향상시킬 수 있는 혁신적인 치료법의 필요성을 인식하고 있습니다. 시장이 보다 효과적인 치료법을 제공하기 위해 노력하면서 연구개발에 대한 투자가 크게 증가했습니다. 이에 따라 신약 후보물질 탐색, 치료 접근법 및 임상시험이 활발히 진행되고 있습니다. 새로운 항진균제, 병용요법, 면역조절 요법의 개발은 세계 크립토콕쿠스증에 대한 긴급한 대응에 의해 추진되고 있습니다. 공중 보건에 대한 인식은 학계, 제약 회사 및 연구 기관의 협력을 촉발시켰습니다. 크립토콕쿠스증은 단순한 의학적인 문제가 아니라 사회적 문제라는 인식은 이해관계자들이 혁신적인 해결책을 위해 협력하도록 유도하고 있습니다. 연구 파트너십, 정부 구상, 비영리 단체는 크립토콕쿠스증 치료제 분야를 발전시키기 위해 서로 자원을 공유하고 있습니다. 또한 공중보건에 대한 인식이 높아지면서 벤처캐피털과 자금 지원 단체의 투자도 증가하고 있습니다. 시장 확대 가능성과 생명을 위협하는 전염병에 구상하는 인도주의적 측면이 결합되어 연구와 임상시험에 대한 자금 지원이 이루어지고 있습니다.

진균 감염증의 복잡성이 중요한 과제 : 크립토콕쿠스증과 같은 진균 감염증은 복잡하며, 효과적인 치료법을 개발하기 위해서는 진균 생물학, 숙주와의 상호작용, 내성 메커니즘을 심층 이해할 필요가 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 크립토콕쿠스증 치료제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율과 예측
    • 치료제별(Amphotericin B, Flucytosine, Fluconazole, 기타)
    • 유통 채널별(병원, 소매 약국, 전문 클리닉, 기타)
    • 지역별
    • 기업별(주요 5사의 점유율)
  • 시장 맵
    • 치료제별
    • 유통 채널별
    • 지역별

제6장 북미 크립토콕쿠스증 치료제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율과 예측
    • 치료제별
    • 판매채널별
    • 국가별

제7장 유럽 크립토콕쿠스증 치료제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율과 예측
    • 치료제별
    • 유통 채널별
    • 국가별

제8장 아시아태평양 크립토콕쿠스증 치료제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율과 예측
    • 치료제별
    • 유통 채널별
    • 국가별

제9장 남미 크립토콕쿠스증 치료제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 유통 채널별
    • 국가별

제10장 중동 및 아프리카 크립토콕쿠스증 치료제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 유통 채널별
    • 국가별

제11장 시장 역학

  • 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 최근 개발
  • 합병·인수
  • 치료제 출시

제13장 경쟁 구도

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.(Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

제14장 전략적 제안

제15장 조사회사 소개·면책사항

KSA 23.11.06

The Global Cryptococcosis Therapeutics Market, valued at USD 4.67 Billion in 2022, is expected to exhibit steady growth with a CAGR of 4.34% through 2028 and expected to reach USD 6.04 Billion in 2028. Cryptococcosis predominantly manifests as a pulmonary and central nervous system infection, exhibiting symptoms ranging from mild respiratory issues to severe neurological complications. The causative fungus is commonly found in the environment, particularly in soil contaminated by bird droppings. When inhaled, the fungal spores can lead to infections, especially in individuals susceptible to such conditions. The increasing prevalence of immunocompromised patients, driven by factors like the HIV/AIDS epidemic, organ transplants, and other immunosuppressive states, has significantly contributed to the escalating burden of cryptococcosis. As research endeavors continue to yield improved treatment options, the cryptococcosis therapeutics market is poised for growth. Collaborative efforts involving pharmaceutical companies, academic institutions, and public health organizations will be pivotal in advancing these innovations. With the emergence of new antifungal agents, combination therapies, and formulations, the outlook for individuals affected by cryptococcosis is expected to improve, enhancing their quality of life and survival rates.

Primary Market Drivers

Rising Prevalence of Immunocompromised Conditions Drives the Cryptococcosis Therapeutics Market: In recent years, there has been a noticeable surge in the number of individuals grappling with immunocompromised conditions. The global HIV/AIDS epidemic remains a significant contributor to the prevalence of cryptococcosis. Despite strides in HIV treatment and prevention, many individuals still lack access to adequate healthcare, rendering them susceptible to opportunistic infections such as cryptococcosis. The increasing prevalence of organ transplantation and cancer treatments offers newfound hope to patients while simultaneously weakening their immune systems. As medical advancements extend the lifespans of organ transplant recipients and cancer survivors, the population living with compromised immune systems is on the rise. This upward trajectory in cryptococcosis prevalence among immunocompromised individuals has catalyzed the development of cryptococcosis therapeutics. Consequently, this market has witnessed a surge in research and development endeavors. Pharmaceutical companies are striving to create drugs that are more effective, less toxic, and accessible to a broader patient base. Notable treatment options for cryptococcosis include antifungal drugs like amphotericin B, fluconazole, and flucytosine. However, these medications may have limitations in terms of efficacy and potential side effects, driving the need for innovative therapeutic solutions. Researchers are actively exploring novel antifungal compounds, combination therapies, and immune-modulating agents to enhance treatment outcomes and alleviate the burden of cryptococcosis among immunocompromised patients.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.67 Billion
Market Size 2028USD 6.04 Billion
CAGR 2023-20284.34%
Fastest Growing SegmentFlucytosine
Largest MarketNorth America

Rising Public Health Awareness Propels the Cryptococcosis Therapeutics Market: The upsurge in public health awareness has correspondingly generated demand for effective cryptococcosis treatments. This demand, in turn, has stimulated growth within the cryptococcosis therapeutics market. Pharmaceutical companies and researchers have recognized the necessity for innovative therapies to combat this fungal infection and enhance patients' quality of life. Investments in research and development have surged substantially as the market endeavors to offer more effective treatments. This has instigated the exploration of new drug candidates, therapeutic approaches, and clinical trials. The development of novel antifungal agents, combination therapies, and immunomodulatory treatments has been driven by the growing urgency to address the global cryptococcosis burden. Public health awareness has sparked collaboration between academia, pharmaceutical firms, and research institutions. The recognition that cryptococcosis is not just a medical challenge but a societal issue has motivated stakeholders to collaborate on innovative solutions. Research partnerships, governmental initiatives, and nonprofit organizations are pooling resources to advance the field of cryptococcosis therapeutics. Furthermore, heightened public health awareness has garnered investment from venture capitalists and funding organizations. The potential for substantial market expansion, coupled with the humanitarian aspect of addressing a life-threatening infection, has resulted in financial support for research and clinical trials.

Complexity of Fungal Infections Presents Key Challenges: Fungal infections like cryptococcosis are intricate, requiring a profound understanding of fungal biology, host interactions, and resistance mechanisms to develop effective treatments.

Clinical Trial Design Poses Challenges: Conducting clinical trials for antifungal drugs is challenging due to the need for specialized patient populations and appropriate study endpoints.

Affordability and Access Remain Significant Challenges: Ensuring that innovative treatments are affordable and accessible, particularly in resource-limited settings, remains a crucial challenge.

Technological Advancements Drive Market Trends: Advancements in diagnostic techniques have revolutionized cryptococcosis detection, leading to earlier and more accurate diagnoses. Molecular diagnostic methods like polymerase chain reaction (PCR) have enabled the detection of Cryptococcus DNA in patient samples. PCR amplifies specific DNA sequences, enabling the detection of even small amounts of fungal DNA. This technique's sensitivity allows for the identification of the fungus in blood or cerebrospinal fluid, facilitating swift diagnosis and treatment initiation. Antigen detection assays have proven valuable for diagnosing cryptococcosis. These assays identify specific fungal antigens, such as Cryptococcus' capsular polysaccharide, in patient samples. Antigen detection tests are highly sensitive and can be conducted on blood or cerebrospinal fluid, aiding in early infection detection. Advanced imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI) have enhanced the visualization of fungal infections within the body, especially when they have spread to the central nervous system.

Segmental and Regional Insights: The Flucytosine segment dominated the Cryptococcosis Therapeutics market in 2022 and is predicted to continue its expansion. Hospitals, particularly in North America, play a pivotal role in prompt cryptococcosis diagnosis and treatment, owing to their advanced healthcare infrastructure.

Key Market Players

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

Report Scope:

  • In this report, the Global Cryptococcosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Cryptococcosis Therapeutics Market, By Treatment:

  • Amphotericin B
  • Flucytosine
  • Fluconazole
  • Other

Cryptococcosis Therapeutics Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Others

Cryptococcosis Therapeutics Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Cryptococcosis Therapeutics Market.

Available Customizations:

  • Global Cryptococcosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cryptococcosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Amphotericin B, Flucytosine, Fluconazole, Others)
    • 5.2.2. By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Cryptococcosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. United States Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
        • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
        • 6.2.3.1.2.1. By Treatment
        • 6.2.3.1.2.2. By Distribution Channel
      • 6.2.3.2. Canada Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
        • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
        • 6.2.3.2.2.1. By Treatment
        • 6.2.3.2.2.2. By Distribution Channel
      • 6.2.3.3. Mexico Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
        • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
        • 6.2.3.3.2.1. By Test
        • 6.2.3.3.2.2. By Distribution Channel

7. Europe Cryptococcosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2.
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Treatment
        • 7.2.4.1.2.2. By Distribution Channel
      • 7.2.4.2. Germany Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Treatment
        • 7.2.4.2.2.2. By Distribution Channel
      • 7.2.4.3. United Kingdom Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Treatment
        • 7.2.4.3.2.2. By Distribution Channel
      • 7.2.4.4. Italy Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Treatment
        • 7.2.4.4.2.2. By Distribution Channel
      • 7.2.4.5. Spain Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Treatment
        • 7.2.4.5.2.2. By Distribution Channel

8. Asia Pacific Cryptococcosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. China Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
        • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
        • 8.2.3.1.2.1. By Treatment
        • 8.2.3.1.2.2. By Distribution Channel
      • 8.2.3.2. India Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
        • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
        • 8.2.3.2.2.1. By Treatment
        • 8.2.3.2.2.2. By Distribution Channel
      • 8.2.3.3. South Korea Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
        • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
        • 8.2.3.3.2.1. By Treatment
        • 8.2.3.3.2.2. By Distribution Channel
      • 8.2.3.4. Japan Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
        • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
        • 8.2.3.4.2.1. By Treatment
        • 8.2.3.4.2.2. By Distribution Channel
      • 8.2.3.5. Australia Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
        • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
        • 8.2.3.5.2.1. By Treatment
        • 8.2.3.5.2.2. By Distribution Channel

9. South America Cryptococcosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2.
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Treatment
        • 9.2.4.1.2.2. By Distribution Channel
      • 9.2.4.2. Argentina Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Treatment
        • 9.2.4.2.2.2. By Distribution Channel
      • 9.2.4.3. Colombia Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Treatment
        • 9.2.4.3.2.2. By Distribution Channel

10. Middle East & Africa Cryptococcosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
        • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
        • 10.2.3.1.2.1. By Treatment
        • 10.2.3.1.2.2. By Distribution Channel
      • 10.2.3.2. Saudi Arabia Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
        • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
        • 10.2.3.2.2.1. By Treatment
        • 10.2.3.2.2.2. By Distribution Channel
      • 10.2.3.3. UAE Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
        • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
        • 10.2.3.3.2.1. By Treatment
        • 10.2.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Launches

13. Competitive Landscape

  • 13.1. Astellas Pharma Inc
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Glenmark Pharmaceuticals
  • 13.4. Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • 13.5. Novartis AG
  • 13.6. Pfizer Inc
  • 13.7. Asahi Kasei Pharma
  • 13.8. Sigmapharm Laboratories LLC

14. Strategic Recommendations

15. About us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제